The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to overcome kidney disease
The Japan Kidney Association, a nonprofit organization, (Headquarters: Bunkyo-ku, Tokyo; “Japan Kidney Association”) and Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys Pharma”) entered into a collaborative agreement on May 1, 2024, with the aim to develop innovative therapies and raise the awareness to overcome kidney disease. “Kidney disease is increasing against a background of changing […]
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys Pharma”) announced that it has submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase III clinical trial in Japan. The Phase III study is a multicenter, open-label, single arm study in Japanese patients with IgA nephropathy, […]
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Renalys Pharma Is Launched To Bring New Innovative Medicines To Patients In Japan and Other Countries In Asia
Co-founded by Catalys Pacific and SR One, Renalys Pharma is an exemplification of how game-changing life-science biopharma can be created through investor partnerships Tokyo, Japan, January 25, 2024 — Catalys Pacific, a transpacific life science investment firm, and SR One, a transatlantic life sciences investment firm, today announced the launch of Renalys Pharma, Inc., a […]
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy